Results 231 to 240 of about 11,994 (242)
Some of the next articles are maybe not open access.
Naunyn-Schmiedeberg's Archives of Pharmacology, 2023
Qian-Lin Wang +7 more
semanticscholar +1 more source
Qian-Lin Wang +7 more
semanticscholar +1 more source
Safety of Micafungin in Pediatric Clinical Trials
Pediatric Infectious Disease Journal, 2011Pediatric patients with invasive fungal infections are often fragile hosts with multiple underlying conditions. Safety is an important feature of antifungal agents to be used in this setting. This study aims to evaluate safety of micafungin in pediatric patients (
Antonio Arrieta +2 more
openaire +3 more sources
Acute Pancreatitis in a Patient Treated with Micafungin
Clinical Therapeutics, 2007A 73-year-old man (height, 158.2 cm; weight, 49.8 kg) presented with upper abdominal tenderness after 3 weeks of treatment with 150 mg/d of micafungin (3 mg/kg . d) (Mycamine, Astellas Pharma US Inc., Deerfield, Illinois) intravenously for pulmonary aspergillosis accompanied by [DOSAGE ERROR CORRECTED] pulmonary Mycobacterium avium complex (MAC ...
Masatomo Mori +5 more
openaire +3 more sources
Effects of micafungin on the morphology of Aspergillus fumigatus
Journal of Electron Microscopy, 2005The morphological effects of micafungin, a member of a new class of antifungal agents candins, on growing hyphae of Aspergillus fumigatus were studied by the use of Nomarski microscopy, scanning electron microscopy and thin-section electron microscopy.
Yayoi Nishiyama +4 more
openaire +2 more sources
Micafungin-induced immune hemolysis attacks
International Journal of Hematology, 2009The echinocandins provide an attractive new option for prophylactic and empirical treatment of invasive fungal infections in patients with neutropenia after intensive cytotoxic chemotherapy or hematopoietic stem cell transplantation. We present two patients with hematological diseases who experienced massive intravascular hemolysis followed by renal ...
Norio Asou +6 more
openaire +3 more sources
Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
The Annals of Pharmacotherapy, 2019Background: Micafungin is increasingly used in the treatment and prevention of candidiasis in hospitalized patients. Limited data are available from which to assess the risk of drug-induced liver injury (DILI) with micafungin.
Caitlin Mullins +2 more
semanticscholar +1 more source
Population pharmacokinetics of micafungin in adult patients
Diagnostic Microbiology and Infectious Disease, 2008We performed population pharmacokinetic analysis of micafungin in adult patients treated with doses between 12.5 and 200 mg/day. Our analysis identified a breakpoint patient weight of 66.3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those
Donald N. Buell +5 more
openaire +3 more sources
Optimizing Micafungin Dosing in Children
Pediatric Infectious Disease Journal, 2012Wei Zhao +3 more
openaire +5 more sources
Efficacy of micafungin for the treatment of candidemia
European Journal of Clinical Microbiology & Infectious Diseases, 2005Nasia Safdar, David R. Andes
openaire +3 more sources